ALEXION PHARMACEUTICALS, INC.

(ALXN)
End-of-day quote Nasdaq  -  07-19
182.50 USD   +1.70%
05/05Ultomiris met primary endpoint in CHAMPION-NMOSD Phase III trial in adults with neuromyelitis optica spectrum disorder
AQ
04/28Ultomiris approved in the US for adults with generalised myasthenia gravis
AQ
04/26BREAKING PMPRB NEWS : Another Win For Patients And The Innovative Pharmaceutical Industry
AQ
 SummaryQuotesChartsNewsRatingsCompany 
Quotes 5-day view   End-of-day quote. End-of-day quote Nasdaq
07/14/2021 07/15/2021 07/16/2021 07/19/2021 07/20/2021 Date
186.61 180.51 180.03 179.45 182.5 Last
8296251 8410329 10300620 10068090 90506120 Volume
+0.34% -3.27% -0.27% -0.32% +1.70% Change
Company
Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on discovering, development and commercialization of medicines. The Company’s marketed products include ULTOMIRIS, SOLIRIS (eculizumab), STRENSIQ (asfotase alfa), KANUMA (sebelipase alfa) and ANDEXXA (coagulation Factor Xa - [recombinant] inactivated-zhzo). Its ULTOMIRIS product is a long-acting C5 inhibitor, that works by... 
Sector
Pharmaceuticals
Calendar
-
More about the company
Ratings of Alexion Pharmaceuticals, Inc.
Trading Rating : 
Investor Rating :  -
ESG Refinitiv : 
B-
More Ratings
All news about ALEXION PHARMACEUTICALS, INC.
05/05Ultomiris met primary endpoint in CHAMPION-NMOSD Phase III trial in adults with neuromy..
AQ
04/28Ultomiris approved in the US for adults with generalised myasthenia gravis
AQ
04/26BREAKING PMPRB NEWS : Another Win For Patients And The Innovative Pharmaceutical Industry
AQ
04/11PMPRB UPDATE : PMPRB Is Accepting Intervener Leave Applications For SOLIRIS Re-hearing
AQ
03/31SCC Leave Denied In Alexion Pharmaceuticals Inc v Canada (Attorney General)
AQ
03/29PMPRB UPDATE : Supreme Court Refuses To Hear Appeal From Decision Restricting Canada's Pat..
AQ
03/18Chugai Pharmaceutical Co., Ltd. - Notice of the Settlement of Patent Infringement Litig..
AQ
03/17AstraZeneca reaches settlement agreement resolving patent litigation related to Ultomir..
AQ
03/01AstraZeneca and Neurimmune close exclusive global collaboration and licence agreement t..
AQ
03/01Alexion, Astrazeneca's Rare Disease Group and Neurimmune Closes Deal for Commercializin..
CI
02/10AstraZeneca sees $4B in COVID vaccine sales as revenue soars
AQ
02/07PRIORITY NEWS : Referral To EBA Gives PCT Joint Applicants Reasons To Rejoice In 2022
AQ
01/25The 2022 PMPRB Outlook For Pharmaceutical Patentees In Canada
AQ
01/10AstraZeneca and Neurimmune sign exclusive global collaboration and licence agreement to..
AQ
01/07AstraZeneca and Neurimmune sign exclusive global collaboration and licence agreement to..
AQ
More news
News in other languages on ALEXION PHARMACEUTICALS, INC.
04/29ASTRAZENECA : bénéfice lesté de charges exceptionnelles
04/29ASTRAZENECA : bénéfice lesté de charges exceptionnelles début 2022
03/01Alexion, le groupe maladies rares d'Astrazeneca et Neurimmune concluent un accord pour ..
02/10ASTRAZENECA : les recettes liées au Covid vont reculer après une année "record"
02/10ASTRAZENECA : le rachat d'Actelion a étouffé la rentabilité en 2021
More news
Analyst Recommendations on ALEXION PHARMACEUTICALS, INC.
More recommendations
Chart ALEXION PHARMACEUTICALS, INC.
Duration : Period :
Alexion Pharmaceuticals, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Managers and Directors
George Llado Chief Information Officer & Senior Vice President
Indrani M. Franchini Chief Compliance Officer & Executive VP
Rana Strellis SVP-Global Culture & Social Responsibility
Gianluca Pirozzi Head-Clinical Development, Hematology & Nephrology
Uzair Qadeer Chief Diversity Officer & Senior Vice President
Sector and Competitors
1st jan.Capi. (M$)
ALEXION PHARMACEUTICALS, INC.0.00%40 336
CSL LIMITED-3.62%93 394
SAMSUNG BIOLOGICS CO.,LTD.-14.73%43 585
BIOGEN INC.-17.01%29 160
WUXI BIOLOGICS (CAYMAN) INC.-43.92%27 891
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.-22.41%23 276